Triple
T22717591
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Genzyme |
E561775
|
entity |
| Predicate | hasProduct |
P3585
|
FINISHED |
| Object | Myozyme |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Myozyme | Statement: [Genzyme, hasProduct, Myozyme]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Myozyme Context triple: [Genzyme, hasProduct, Myozyme]
-
A.
Fabrazyme
Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
-
B.
Cerezyme
Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
-
C.
Lumizyme
Lumizyme is an enzyme replacement therapy used to treat patients with Pompe disease by supplementing deficient acid alpha-glucosidase.
-
D.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
E.
Strensiq
Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Myozyme Target entity description: Myozyme is an enzyme replacement therapy used to treat Pompe disease, a rare genetic disorder caused by acid alpha-glucosidase deficiency.
-
A.
Fabrazyme
Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
-
B.
Cerezyme
Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
-
C.
Lumizyme
chosen
Lumizyme is an enzyme replacement therapy used to treat patients with Pompe disease by supplementing deficient acid alpha-glucosidase.
-
D.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
E.
Strensiq
Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
- F. None of above.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454fc984819088213b58ee87a002 |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1790ecbc48190926d16b20b674dbd |
completed | April 29, 2026, 3:20 a.m. |
Created at: April 17, 2026, 3:19 p.m.